Combination of paclitaxel and bevacizumab in heavily pre-treated non-small-cell lung cancer (NSCLC) patients: a case series study on 15 Patients

Moulec, Sylvestre Le; Hadoux, Julien; Gontier, Éric; Chargari, Cyrus; Hélissey, Carole; Lamand, V.; Tanz, Rachid; Farace, Françoise; Védrine, Lionel; Bonardel, G.; Soria, Jean‐Charles; Besse, Benjamin

doi:10.1684/bdc.2013.1864

Cited by 7 publications

(8 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Approximately 85 % of patients are diagnosed with non-small cell lung cancer (NSCLC). Modifications of chemotherapy combinations, the addition of monoclonal antibodies, including bevacizumab [ 2 , 3 ] and cetuximab [ 4 , 5 ], and the incorporation of histologic subtype [ 6 ] into treatment decisions have added to the survival of patients with advanced NSCLC. Unfortunately, therapeutic outcomes appear to have reached a plateau, with response rates of 20 to 35 % and median survival of 8 to 12 months [ 7 ].…”

Section: Introductionmentioning

confidence: 99%

Study on expression of lncRNA RGMB-AS1 and repulsive guidance molecule b in non-small cell lung cancer

Yang

et al. 2015

Diagn Pathol

View full text Add to dashboard Cite

BackgroundThe relationships between lncRNAs and tumors have currently become one of the focuses on cancer studies. However, there are a few studies about lncRNAs in non-small cell lung cancer (NSCLC) at present.MethodsMicroarray analysis was designed to study the expression patterns of lncRNAs in three pairs of NSCLC tissues. The expression of lncRNA RGMB-AS1 and repulsive guidance molecule b (RGMB) were detected in 72 paired NSCLC tissues and adjacent normal tissues by qRT-PCR assay. The relations of lncRNA RGMB-AS1 and RGMB expression with clinicopathological factors of NSCLC patients were explored. A549 and SPC-A-1 cells were transfected with siRNA of lncRNA RGMB-AS1 and negative control. RGMB expression level was detected by qRT-PCR assay and western blot analysis.ResultsThe results of microarray found that 571 lncRNAs were differentially expressed in NSCLC tissues (Fold change cut-off: 5.0, P < 0.05), including 304 upregulated and 267 downregulated lncRNAs. The results of qRT-PCR showed that lncRNA RGMB-AS1 expression was significantly higher in NSCLC tissues than in adjacent normal tissues (P < 0.05), while RGMB mRNA showed an opposite trend (P < 0.05). Correlation analysis indicated that the expression of lncRNA RGMB-AS1and RGMB mRNA were inversely correlated (R2 = 0.590, P < 0.05). While lncRNA RGMB-AS1 and RGMB expression levels in NSCLC tissues were associated with the occurrence of differentiation status, lymph node metastases and TNM stage (P < 0.05). Transfection with siRNA of lncRNA RGMB-AS1, subsequent results showed that RGMB mRNA and protein expression were upregulated (P < 0.05) in A549 and SPC-A-1 cells compared to the control groups.ConclusionWe identified lncRNA RGMB-AS1 was upregulated and RGMB was downregulated in NSCLC patients. Both were related to differentiation status, lymph node metastases and TNM stage. Studies also indicated that lncRNA RGMB-AS1and RGMB were inversely correlated.Virtual slidesThe virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/7911587521528276

show abstract

Section: Introductionmentioning

confidence: 99%

Study on expression of lncRNA RGMB-AS1 and repulsive guidance molecule b in non-small cell lung cancer

Yang

et al. 2015

Diagn Pathol

View full text Add to dashboard Cite

show abstract

“…Furthermore, Shaked et al [47] showed that PTX could induce circulating endothelial progenitor mobilization and promote angiogenesis, whereas the combined use of anti-angiogenic drugs such as bevacizumab could enhance the efficacy of PTX. Combined together, the two drugs probably have a profound synergistic effect on the tumor's blood vessels [45]. It has also been suggested that bevacizumab could normalize the tumor blood vessels, improving drug delivery and the immune microenvironment.…”

Section: Discussionmentioning

confidence: 99%

“…Finally, a study of nab-PTX combined with pemetrexed showed a PFS of 4.4 months, an OS of 8.8 months, and an ORR of 14% 42 . Three studies of PTX combined with bevacizumab in previously treated patients with NSCLC reported ORRs of 40.0%-48.8%, DCRs of 75.0%-86.0%, a PFS of 4.6-6.4 months, and an OS of 9.6-14.5 months 43 - 45 . The treatment effects observed in the present study for the nab-PTX and bevacizumab combination were generally consistent with these previous results.…”

Section: Discussionmentioning

confidence: 99%

“…Indeed, paclitaxel is an agent disrupting the normal functioning of the microtubules, preventing cell division and leading to apoptosis; it also has anti-angiogenic effects, probably due to the inhibition of the proliferation of endothelial cells. Bevacizumab is an anti-angiogenesis agent that directly blocks the action of VEGFR 43 - 45 . Animal studies showed that VEGF could reverse the effects of docetaxel, another member of the taxane family along with PTX and that the use of an anti-VEGF drug could restore the activity of docetaxel 46 .…”

Section: Discussionmentioning

confidence: 99%

“…In two studies of sb-PTX with bevacizumab, the rates of neutropenia were 50.0% and 19.3% 53 . In PTX combined with bevacizumab, the rates of neutropenia were 20%-37.5% 43 - 45 . The toxicity profile in the present study falls within the reported ranges but in the lower end of those ranges.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Nab-paclitaxel in combination with Bevacizumab in patients with non-squamous non-small cell lung cancer after failure of at least one prior systemic regimen

Hao

Zhu

et al. 2020

J. Cancer

View full text Add to dashboard Cite

Background: Most patients with non-small cell lung cancer (NSCLC) experience disease progression after first-line treatment. The efficacy and safety of the nab-paclitaxel (nab-PTX) and bevacizumab combination as the second or further line of treatment in patients with advanced NSCLC have not been reported yet. Objective: To evaluate the efficacy and safety of the nab-PTX and bevacizumab combination in patients with advanced non-squamous (NSQ) NSCLC after failure of at least one prior systemic regimen. Methods: Patients with advanced (stage IV) NSQ NSCLC who received the nab-PTX and bevacizumab combination as the second or further line treatment between February 2012 and December 2018 at the Cancer Hospital of the Chinese Academy of Medical Sciences (Beijing, China) were included in this retrospective study. The main outcomes included the objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety. Results: Thirty-four patients received 1-27 cycles (median, four cycles) of treatment; 67.6% (23/34) patients had undergone at least two lines of previous treatment. The ORR and disease control rates were 26.5% (9/34) and 82.4% (28/34), respectively. The median PFS and OS were 6.0 (95% CI=2.9-7.2) and 11.0 (95% CI=7.8-18.7) months, respectively. The multivariable analyses indicated that the combined use of other drugs and pleural metastasis were respectively associated with better PFS (hazard ratio=0.354, 95% CI=0.134-0.935, P=0.036) and OS (hazard ratio=0.540, 95% CI=0.118-0.980, P=0.046). The most frequent grade 3-4 adverse events (AEs) were neutropenia 20.6% (7/34), leukopenia 8.8% (3/34), and anemia 5.9% (2/34). No grade 5 AE occurred. Conclusion: Combined nab-PTX and bevacizumab might be an effective treatment regimen for patients with advanced NSQ NSCLC after failure of at least one prior systemic regimen, but studies have to validate those findings.

show abstract

Low expression of long noncoding RNA CASC2 indicates a poor prognosis and regulates cell proliferation in non-small cell lung cancer

Liu

et al. 2016

Tumor Biol.

View full text Add to dashboard Cite

Recently, long noncoding RNAs (lncRNAs) have been shown to have important regulatory roles in human cancer biology. The aim of this study was to evaluate the expression and biological role of lncRNA CASC2 in non-small cell lung cancer (NSCLC). By bioinformatics analysis, we found that CASC2 was significantly decreased in NSCLC. qRT-PCR was performed to investigate the expression of CASC2 in tumor tissues and corresponding non-tumor NSCLC tissues from 76 patients. The lower expression of CASC2 was remarkably correlated with advanced TNM stage and tumor size. Multivariate analyses found that CASC2 expression served as an independent predictor for overall survival of NSCLC. Moreover, overexpression of CASC2 significantly inhibited NSCLC cell proliferation both in vitro and in vivo. In conclusion, our study demonstrated that CASC2 is involved in the development and progression of NSCLC and shows that CASC2 may be a potential diagnostic and target for new therapies in patients with NSCLC.

show abstract

Combination of paclitaxel and bevacizumab in heavily pre-treated non-small-cell lung cancer (NSCLC) patients: a case series study on 15 Patients

Cited by 7 publications

References 32 publications

Study on expression of lncRNA RGMB-AS1 and repulsive guidance molecule b in non-small cell lung cancer

Study on expression of lncRNA RGMB-AS1 and repulsive guidance molecule b in non-small cell lung cancer

Nab-paclitaxel in combination with Bevacizumab in patients with non-squamous non-small cell lung cancer after failure of at least one prior systemic regimen

Low expression of long noncoding RNA CASC2 indicates a poor prognosis and regulates cell proliferation in non-small cell lung cancer

Contact Info

Product

Resources

About